In March 2011, the FDA approved belimumab (Benlysta) for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus who are receiving standard therapy. Belimumab is a fully human monoclonal antibody directed against BLyS (B lymphocyte stimulator). BLyS, a member of the TNF ligand super family, promotes the survival and maturation of B cells. For patients on standard of care therapy and without active severe renal or central nervous system lupus, belimumab has been shown to be effective and safe. Further information will be gathered in the open label extensions of the phase II and III trials and post-marketing experience.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
It has been great pleasure to work with Libertas Academica and the communications between us have always been fast and efficient. I am looking forward to working with Libertas Academica more and more!
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2013 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)